Migrenli hastalarda serum GLP-1 ve DPP-4 düzeyinin değerlendirilmesi
Yükleniyor...
Dosyalar
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Düzce Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Migren, dünyada bir milyar kişiyi etkileyen ve günlük yaşamda kısıtlılığa yol açan nörovasküler bir bozukluktur. Patofizyolojisi hakkında birçok teori öne sürülse de halen kesin bir tedavisi bulunmamaktadır. Ataklar sırasında oluşan baş ağrısı, trigeminal sinir uçlarının aktivasyonu ile ilişkilidir. Glukagon benzeri peptid-1 (GLP-1), insülinin parçalanmasını engellediği düşünülen bir hormondur. İnce bağırsaklardaki L hücrelerinde, pankreasta alfa hücrelerinde ve beyin sapındaki nukleus traktus solitarius (NTS) gibi birçok beyin bölgesinde reseptörleri bulunmaktadır. Merkezi sinir sisteminde nöroprotektif birçok mekanizmada rol oynamaktadır. Aynı zamanda çeşitli nörodejeneratif hastalıkların tedavisinde GLP-1 analogları kullanılmaktadır. Dipeptidil peptidaz-4 (DPP-4), GLP-1' i parçalayan proteaz ailesine ait bir enzimdir. İnkretinleri ve iştah baskılayıcı nöropeptidleri bileşenlerine ayırarak inaktif hale getirmektedir. Bu çalışmanın amacı, migren hastalarında GLP-1 ve DPP-4 enzim düzeylerinin migren patofizyolojisi ile ilişkili olup olmadığını göstermek ve migren tedavisinde yeni bir yaklaşım sağlayabilmektir. Çalışmamızda, migren tanısı almış 42 hasta migrenli grup olarak; migren tanısı almamış ve hastanedeki diğer polikliniklere başvurmuş 42 kişi kontrol grubuna seçilerek 2 grup oluşturulmuştur. Gönüllülerden en az 8 saat açlıktan sonra kanları alınarak serumlarında çalışma yapılmıştır. Serum GLP-1 ve DPP-4, ELİSA metodu ile ölçülüp istatistiksel analiz SPSS 22.0 programı ile yapılmıştır. Elde edilen sonuçlar migren hastalarının serumlarında, kontrol grubuna göre GLP-1 ve DPP-4 düzeylerinin anlamlı derecede düşük olduğu bulunmuştur (p<0,001). Bu bilgiler ışığında GLP-1' in ve DPP-4' ün migrenli hastalarda azalmış olması, baş ağrısının oluşumunda bir faktör olarak değerlendirilebilir. Bu durum migrenli hastalarda diyabetin daha fazla görülme sıklığını açıklayabilir.
Migraine is a neurovascular disorder that affects one billion people in the world and causes limitations in daily life. Although many theories have been suggested about its pathophysiolgy, there is still no definitive treatment. Headache occuring during attacks is associated with activation of trigeminal nerve endings. Glucagon-like peptide-1 (GLP-1) is a hormone that is thought to inhibit the breakdown of insulin. It has receptors in many brain regions, such as the nucleus tractus solitarius (NTS) in the brainstem and L-cells in the small intestine, alpha cells in the pancreas. It plays a role in many neuroprotective mechanisms in the central nervous system. At the same time, GLP-1 analogs are used in the treatment of various neurodegenerative diseases. Dipeptidyl peptidase-4 (DPP-4) is an enzyme belonging to the protease family that degrades GLP-1. It decomposes incretins and appetite suppressing neuropeptides and renders them inactive. The aim of this study is to show whether GLP-1 and DPP-4 enzyme levels are associated with migraine pathophysiology in migraine patients and to provide a new approach in the treatment of migraine. In this study, 42 patients diagnosed with migraine as the migraine group; 42 people who were not diagnosed with migraine and applied to other outpatient clinics in the hospital were selected as the control group. After fasting for at least 8 hours, blood samples were taken from the volunteers and their serums were studied. Serum GLP-1 and DPP-4 were measured by ELISA method and statistical analysis was performed with SPSS 22.0 program. The results obtained showed that the serum levels of GLP-1 and DPP-4 were significantly lower in the sera of migraine patients compared to the control group (p<0.001). In the light of this information, the decrease in GLP-1 in patients with migraine can be considered as a factor in the formation of headache. This may explain the higher incidence of diabetes in patients with migraine.
Migraine is a neurovascular disorder that affects one billion people in the world and causes limitations in daily life. Although many theories have been suggested about its pathophysiolgy, there is still no definitive treatment. Headache occuring during attacks is associated with activation of trigeminal nerve endings. Glucagon-like peptide-1 (GLP-1) is a hormone that is thought to inhibit the breakdown of insulin. It has receptors in many brain regions, such as the nucleus tractus solitarius (NTS) in the brainstem and L-cells in the small intestine, alpha cells in the pancreas. It plays a role in many neuroprotective mechanisms in the central nervous system. At the same time, GLP-1 analogs are used in the treatment of various neurodegenerative diseases. Dipeptidyl peptidase-4 (DPP-4) is an enzyme belonging to the protease family that degrades GLP-1. It decomposes incretins and appetite suppressing neuropeptides and renders them inactive. The aim of this study is to show whether GLP-1 and DPP-4 enzyme levels are associated with migraine pathophysiology in migraine patients and to provide a new approach in the treatment of migraine. In this study, 42 patients diagnosed with migraine as the migraine group; 42 people who were not diagnosed with migraine and applied to other outpatient clinics in the hospital were selected as the control group. After fasting for at least 8 hours, blood samples were taken from the volunteers and their serums were studied. Serum GLP-1 and DPP-4 were measured by ELISA method and statistical analysis was performed with SPSS 22.0 program. The results obtained showed that the serum levels of GLP-1 and DPP-4 were significantly lower in the sera of migraine patients compared to the control group (p<0.001). In the light of this information, the decrease in GLP-1 in patients with migraine can be considered as a factor in the formation of headache. This may explain the higher incidence of diabetes in patients with migraine.
Açıklama
Anahtar Kelimeler
Fizyoloji, Physiology
